Testing JKN2403 for COPD: a new treatment option
Part of Lungs & breathing clinical trials.
This study tests an experimental drug called JKN2403 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve breathing compared to a placebo (a dummy pill).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of COPD and a history of smoking or exposure to things that can cause COPD.
- You are on a stable, regular treatment plan for your COPD before the study starts.
- You do not have asthma or any other major lung disease besides COPD.
- You have not had a recent COPD flare-up or infection requiring treatment.
- You do not have an autoimmune disease that requires immune-suppressing medication, or a history of serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called WIN378 in people with moderate-to-severe COPD (chronic lung disease). It will check if the drug is safe and how the body processes it, which may help improve breathing and reduce flare-ups.
This study tests an experimental drug for people with moderate to severe COPD, especially those with chronic bronchitis. It aims to see how the drug affects certain markers in your body and whether it helps with your COPD symptoms.
This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This study tests a new injectable medicine called JKN2401 to see if it can reduce COPD flare-ups and improve breathing for people with moderate-to-severe COPD. It is a phase 3 trial, which means it's a late-stage test to confirm the treatment works and is safe.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.